Nilamben Patel, DO
Allergy & Immunology · North Port, FLNPI 1174941645
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 50.8% of the total. 2025 is the largest year on record at $34,614, more than ten times the $110 reported in 2019.
Across 316 payments — averaging $145.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$23K
- Novartis$11K
- Sanofi$8K
- Regeneron Healthcare Solutions, Inc.$905
- CSL Behring$860
- GSK$654
- plus $1K from 17 others
What the payments were for
- Consulting fees$12,55427%
- Speaking & faculty fees$19,41142%
- Travel & lodging$7,38416%
- Food & beverage$6,69915%
- Education$770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 89 | $23,437 |
| Novartis | 21 | $11,228 |
| Sanofi | 44 | $7,992 |
| Regeneron Healthcare Solutions, Inc. | 38 | $905 |
| CSL Behring | 37 | $860 |
| GSK | 34 | $654 |
| AstraZeneca | 9 | $164 |
| Octapharma USA, Inc. | 6 | $154 |
| Pharming Healthcare, Inc. | 8 | $140 |
| Genentech USA, Inc. | 5 | $112 |
| Grifols USA, LLC | 4 | $89 |
| Kaleo, Inc. | 5 | $80 |
| Lilly USA, LLC | 2 | $58 |
| Biocryst US Sales Co., LLC | 3 | $52 |
| Optinose US, Inc. | 2 | $47 |
| Ionis Pharmaceuticals, Inc. | 2 | $37 |
| Pfizer | 1 | $23 |
| ADMA Biomanufacturing LLC | 1 | $17 |
| Phadia US Inc. | 1 | $17 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
| Galderma Laboratories, L.p. | 1 | $15 |
| Boehringer Ingelheim | 1 | $15 |
| Genentech, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$46,125 in reported general payments places this provider in the 85th percentile of 204 allergy & immunology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HyqviaIgg/Hyaluronidase,recombinant | 62 | $385,991 |
| Dupixent PenDupilumab | 32 | $181,133 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $91,456 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $11,408 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,522 |
| Ipratropium Bromide | 60 | $1,480 |
| Azelastine Hcl | 59 | $1,040 |
| Levocetirizine Dihydrochloride | 43 | $588 |
| Montelukast Sodium | 24 | $118 |
| Prednisone | 23 | $54 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia | $23,437 | $385,99162 claims |
| CSL BehringPrivigen | $860 | $91,45613 claims |
| GSKTrelegy Ellipta | $654 | $11,40814 claims |
| AstraZenecaSymbicort | $164 | $2,52211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 204 allergy & immunology providers in Florida.
Other allergy & immunology in North Port
- Dennis LedfordTampa$1.2M
- Nina RamirezMiami$833K
- Thomas WestbrookPensacola$810K
- Shahnaz FattehPlantation$677K
- Thomas CasaleTampa$382K
- Thomas JohnsonGainesville$361K
- Mark GlaumTampa$337K
- Alan HalseyValrico$243K
- Steve DormanJacksonville$208K
- Juan Carlos CardetTampa$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.